West Pharmaceutical Services, a key player in the pharmaceutical supply chain, produces essential packaging components for injectable drugs, including those used in vaccines and biologics.
The company's stock has seen a significant recovery, rising 37% year-to-date and 45% over the past year, following a challenging period marked by a sharp decline in February 2025 when it guided earnings per share (EPS) much lower than expected. Recent financial results show a 13.8% increase in Q2 sales to $872 million and a 28.8% rise in adjusted EPS to $2.37, surpassing analyst expectations.
The growth is partly driven by the demand for GLP-1 drugs, which now account for 18% of revenue. Management has raised its sales and EPS guidance for 2026, indicating a positive outlook. The stock trades at approximately 42 times the midpoint of the 2026 guidance, which reflects a recovery in earnings rather than a decline.
With a new CEO at the helm and strategic moves like selling a business unit and initiating a stock buyback, West is positioned for further growth. Investors are closely watching the stock's performance as it approaches key resistance levels, with $383 being a critical price point for potential breakout momentum